Literature DB >> 29703439

Left Atrial Reverse Remodeling After Catheter Ablation of Nonparoxysmal Atrial Fibrillation in Patients With Heart Failure With Reduced Ejection Fraction.

Takafumi Oka1, Koichi Inoue2, Koji Tanaka1, Yuichi Ninomiya1, Yuko Hirao1, Nobuaki Tanaka1, Masato Okada1, Hiroyuki Inoue1, Ryo Nakamaru1, Yasushi Koyama1, Atsunori Okamura1, Katsuomi Iwakura1, Yasushi Sakata3, Kenshi Fujii1.   

Abstract

The efficacy of catheter ablation (CA) of nonparoxysmal atrial fibrillation (PAF) in patients with left ventricular systolic dysfunction is controversial. We investigated the outcomes of CA for non-PAF in patients with reduced left ventricular ejection fraction (LVEF) and the impact of early left atrial (LA) reverse remodeling on these outcomes. A total of 251 consecutive patients who underwent CA for non-PAF were divided into 2 groups (reduced: preoperative LVEF ≤55%, LVEF: 46.5 ± 8.7%, n = 63; normal: >55%, 65.8 ± 5.8%, n = 188). We analyzed the 4-year atrial fibrillation- or atrial tachycardia (AT)-free survival rate and assessed changes in LVEF, hemodynamics, and LA reverse remodeling at the end of a 90-day blanking period. We also evaluated LA reverse remodeling in patients with and without recurrence. The atrial fibrillation- or AT-free survival rates were similar (reduced vs normal 48% vs 42%, p = 0.32). The reduced group exhibited significant LVEF improvement (before vs after, 46.5 ± 8.7% vs 58.4 ± 11.5%, p<0.001), reduced mitral regurgitation, and spectral tissue Doppler-derived index, and had greater percent maximum left atrial volume reduction (reduced vs normal 25.3 ± 18.2% vs 19.3 ± 16.2%, p = 0.014). Percent maximum left atrial volume reduction was greater in patients without recurrence (with recurrence vs without recurrence 17.3 ± 16.7% vs 25.4 ± 16.1%, p<0.001). In conclusion, the efficacy of non-PAF CA in patients with reduced LVEF was comparable with that in patients with normal LVEF. Greater LA reverse remodeling in these patients suggests an association with a reduced recurrence rate.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29703439     DOI: 10.1016/j.amjcard.2018.03.026

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Effect of pulmonary vein isolation on the relationship between left atrial reverse remodeling and sympathetic nerve activity in patients with atrial fibrillation.

Authors:  Yusuke Mukai; Hisayoshi Murai; Takuto Hamaoka; Hiroyuki Sugimoto; Oto Inoue; Chiaki Goten; Takashi Kusayama; Shin-Ichiro Takashima; Takeshi Kato; Soichiro Usui; Kenji Sakata; Shigeo Takata; Masayuki Takamura
Journal:  Clin Auton Res       Date:  2022-06-23       Impact factor: 5.625

2.  Early recurrence during the blanking period and left atrial reverse remodeling after catheter ablation for non-paroxysmal atrial fibrillation.

Authors:  Takafumi Oka; Yasushi Koyama; Koji Tanaka; Yuko Hirao; Nobuaki Tanaka; Masato Okada; Issei Yoshimoto; Ryo Kitagaki; Atsunori Okamura; Katsuomi Iwakura; Yasushi Sakata; Kenshi Fujii; Koichi Inoue
Journal:  Int J Cardiol Heart Vasc       Date:  2020-07-23

3.  A comparison of clinical outcomes following atrial fibrillation ablation for heart failure patients with preserved or reduced left ventricular function: A systematic review and meta-analysis.

Authors:  Gaurav Panchal; Chun Shing Kwok; Adrian Morley-Davies; Donah Zachariah; Thanh Phan
Journal:  Indian Pacing Electrophysiol J       Date:  2021-10-05

4.  Persistence of left atrial abnormalities despite left atrial volume normalization after successful ablation of atrial fibrillation.

Authors:  Hiroshi Kawakami; Katsuji Inoue; Takayuki Nagai; Akira Fujii; Yasuhiro Sasaki; Yukari Shikano; Namiko Sakuoka; Maki Miyazaki; Yasunori Takasuka; Shuntaro Ikeda; Osamu Yamaguchi
Journal:  J Arrhythm       Date:  2021-08-28

Review 5.  Echocardiographic Assessment of Atrial Function: From Basic Mechanics to Specific Cardiac Diseases.

Authors:  Katsuji Inoue; Hiroshi Kawakami; Yusuke Akazawa; Haruhiko Higashi; Takashi Higaki; Osamu Yamaguchi
Journal:  J Cardiovasc Dev Dis       Date:  2022-02-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.